Structure Therapeutics (NASDAQ:GPCR) Announces Earnings Results, Misses Expectations By $0.33 EPS

Structure Therapeutics (NASDAQ:GPCR) released its earnings results on Monday. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.33), FiscalAI reports.

Structure Therapeutics Stock Up 5.2%

Shares of Structure Therapeutics stock traded up $1.06 on Monday, reaching $21.41. 1,235,627 shares of the stock were exchanged, compared to its average volume of 966,527. The business has a 50 day moving average price of $30.52 and a two-hundred day moving average price of $47.81. The firm has a market capitalization of $1.49 billion, a price-to-earnings ratio of -21.41 and a beta of -1.12. Structure Therapeutics has a twelve month low of $18.70 and a twelve month high of $94.90.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Citigroup restated a “market outperform” rating on shares of Structure Therapeutics in a research note on Friday, August 7th. HC Wainwright reiterated a “buy” rating on shares of Structure Therapeutics in a research note on Wednesday, September 9th. Citizens Jmp reissued a “market outperform” rating and set a $110.00 price objective on shares of Structure Therapeutics in a report on Wednesday, September 9th. Canaccord Genuity Group set a $111.00 target price on Structure Therapeutics in a research report on Friday, August 7th. Finally, Weiss Ratings upgraded Structure Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $110.91.

About Structure Therapeutics

Structure Therapeutics is a clinical-stage biopharmaceutical company developing medicines for metabolic and other chronic diseases. Its research approach uses structural biology and computational methods to identify and design small-molecule drug candidates.

The company’s pipeline includes aleniglipron, an oral small-molecule GLP-1 receptor agonist being developed for obesity and related metabolic conditions. Structure Therapeutics is also advancing other drug candidates targeting biological pathways associated with metabolic disease.

Founded in 2016, the company has operations in the United States and China.